Evidence map›Paper›PMID 42116316›Full record

ReviewMedicine2026

Autosomal dominant inheritance of a heterozygous mutation in HTRA1: A case report and literature review.

Jianzhong Shu, Jinrong Li

Abstract readCase ReportsReview
In one paragraph

Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jianzhong ShuEncephalopathy Department, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleHeterozygous mutations in the gene encoding HtrA serine protease 1 (HTRA1) can cause autosomal dominant cerebral small-vessel disease (CSVD), presenting with clinical features that differ slightly from other hereditary CSVD subtypes. Only a limited number of cases have been documented globally. PATIENT CONCERNS: A 51-year-old man presented with more than 2 years of left lower limb weakness, which had acutely worsened over the preceding day. Brain magnetic resonance imaging (MRI) revealed ischemic demyelinating changes in the white matter. DIAGNOSES: Genetic sequencing identified a heterozygous HTRA1 mutation. Follow-up testing confirmed that both of his daughters also carried the same heterozygous mutation.

interventionsManagement focused on secondary prevention, risk-factor control, and lifestyle modification. OUTCOMES: A 6-month follow-up cranial MRI showed no new lesions, and the patient remained clinically stable without disease progression during 1 year of monitoring. LESSONS: Heterozygous HTRA1 mutations may present as autosomal-dominant CSVD, and genetic testing is central to establishing the diagnosis.

Indexed as

Cerebral Small Vessel DiseasesHigh-Temperature Requirement A Serine Peptidase 1MutationGenes, DominantHeterozygoteHumansMagnetic Resonance ImagingMaleMiddle AgedHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanautosomal dominant disordercase reportcerebral small-vessel diseaseHTRA1 gene with heterozygous mutation

Identifiers

PMID42116316
PMCPMC13166807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.